Researchers developed the seats to measure biometrics during ‘natural’ processes
With 1 million new cases of congestive heart failure diagnosed each year, a revolutionary product is making it easier for hospitals to monitor patients with the condition in the comfort of their own homes.
A toilet-seat based cardiovascular monitoring system created by a team of Rochester Institute of Technology researchers, aims to lower the hospital readmission rates of patients with congestive heart failure. The toilet seats, which will be brought through the FDA clearance process by the researchers’ company Heart Health Intelligence, would be purchased by hospitals and issued to heart failure patients after discharge. The toilet seats are equipped to measure the electrical and mechanical activity of the heart, and can monitor heart rate, blood pressure, blood oxygenation levels, and the patient’s weight and stroke volume, which is the amount of blood pumped out of the heart at every beat. Algorithms analyze the data, and with further development, will alert advanced practice providers of a deteriorating condition. A report will be passed along to cardiologists who will then determine if intervention is necessary.
Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that developed the toilet seats.
“Typically, within 30 days of hospital discharge, 25 percent of patients with congestive heart failure are readmitted,” said Conn. “After 90 days of hospital discharge, 45 percent of patients are readmitted. And the Centers for Medicare and Medicaid Services is penalizing hospitals for readmitting patients for heart failure.”
Conn, the company’s chief executive officer, further explains that using the national average for readmission rates, the penalty alone for readmitting 150 patients is approximately $500,000 annually. The total cost of providing 150 patients with their own monitored toilet seats from HHI is $200,000. With that investment, he says, hospital systems will save more than double their initial investment within one year.
According to Conn, who earned three degrees from RIT—a bachelor’s degree and a master’s degree in electrical engineering in 2011 and 2013, respectively, and a doctoral degree in microsystems engineering in 2016—the system will pick up deteriorating conditions before the patients even realize they are symptomatic. And with the rapid data analysis, interventions can be as simple as a drug change or short office visit, instead of an admission to the hospital.
HHI, which joined RIT’s Venture Creations business incubator earlier this year, is now focused on moving the product forward. The team is heavily involved in writing grants for additional funding and networking, and human-subject testing and pre-clinical studies are well underway. Conn and his team are working on approving the product with the FDA and rolling it out across the country.
The Latest on: Congestive heart failure
via Google News
The Latest on: Congestive heart failure
- Diabetes drug shows promise in treating and reversing heart failureon November 21, 2020 at 5:59 am
It may progress to congestive heart failure due to the buildup of fluids in the lungs, liver, and lower extremities. Underlying causes of heart failure include coronary artery disease, high blood ...
- New voices chosen to elevate the link between type 2 diabetes, heart disease and strokeon November 16, 2020 at 11:44 am
New voices chosen to elevate the link between type 2 diabetes, heart disease and strokeARLINGTON, Va. 16, 2020The American Heart Association® and American Diabetes Association's® Know Diabetes by ...
- Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart ...on November 16, 2020 at 4:32 am
(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records related to heart failure and hypertrophic ...
- COVID-19 And Its Effects On The Heart: OSF Health Careon November 15, 2020 at 6:32 pm
A growing number of studies indicate that many COVID-19 survivors experience some type of heart damage, American Heart Association reports.
- AstraZeneca, looking for clarity, snags ImpediMed sensors for heart, kidney failure trialson November 13, 2020 at 5:06 am
To capture a clearer picture of patients’ progress in its clinical trials for heart failure and chronic kidney disease, AstraZeneca has tapped the Australian developer ImpediMed and its devices that ...
- Type 2 diabetes: Is losing fat key to reducing heart failure risk?on November 13, 2020 at 2:00 am
A new study has found that an effective way of reducing heart failure risk in type 2 diabetes may be by losing fat mass, but not muscle mass.
- Vida Health Launches Virtual Congestive Heart Failure Management Programon November 12, 2020 at 3:17 pm
Vida Health will launch a virtual congestive heart failure management program to its national payer customers in Dec. with a full rollout in Jan. 2021 ...
- Virtual care proving crucial for heart and stroke survivorson November 12, 2020 at 6:43 am
I know we followed the government regulations strictly and had virtually no contact with anyone.” A Heart & Stroke Foundation survey released Thursday found a significant number of people living with ...
- Qatar- Heart Hospital treats thousands of patientson November 12, 2020 at 1:00 am
About 3,000 patients have received care through the teleconsultation service introduced by the Advanced Heart Failure Unit at Hamad Medical Corporation's (HMC) Heart Hospital as part of efforts to ...
- New source of lymphatic system leak discovered in children with rare open heart surgery complicationon November 11, 2020 at 11:35 am
Interventional radiologists with Nemours Children's Health System have identified a new source of abnormal lymphatic flow between the liver and the lungs that may be responsible for some cases of ...
via Bing News